STOCK TITAN

Mind Medicine Inc - MNMD STOCK NEWS

Welcome to our dedicated news page for Mind Medicine (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mind Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mind Medicine's position in the market.

Rhea-AI Summary
MindMed, a clinical stage biopharmaceutical company, will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD) at upcoming medical conferences. The presentations will focus on the epidemiology and growing burden of GAD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announces the presentation of posters at upcoming medical conferences on the impact of COVID-19 on Generalized Anxiety Disorder in European and U.S. populations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
conferences
-
Rhea-AI Summary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has decided to voluntarily delist its common shares from Cboe Canada to focus on its Nasdaq listing, citing cost savings and increased shareholder value as key reasons. The delisting will be effective on April 10, 2024, with trading continuing on Nasdaq, providing shareholders with ample liquidity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
Rhea-AI Summary
Mind Medicine (MNMD) to participate in Leerink Partners 2024 Global Biopharma Conference for investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.02%
Tags
conferences
-
Rhea-AI Summary
Numinus Wellness Inc. congratulates Mind Medicine on positive data from Phase 2b clinical trial of MM120 for GAD, showing significant improvement in anxiety treatment. FDA designates MM120 as a breakthrough therapy for GAD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
-
Rhea-AI Summary
Mind Medicine (MindMed) Inc. announces the pricing of an underwritten offering of common shares, expecting gross proceeds of approximately $175 million. New investors Deep Track Capital and Commodore Capital are part of the private placement. Leerink Partners and Cantor are acting as joint bookrunning managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
51.52%
Tags
Rhea-AI Summary
MindMed's MM120 program for generalized anxiety disorder (GAD) receives breakthrough designation from FDA, showing significant clinical response and remission rates. Phase 2b study demonstrates durable activity through Week 12, leading to plans for Phase 3 clinical program initiation in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
51.52%
Tags
-
Rhea-AI Summary
MindMed announces update on MM120 in Generalized Anxiety Disorder (GAD) with Phase 2b results and Phase 1 trial for oral dissolving tablet (ODT) formulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.01%
Tags
conferences
-
Rhea-AI Summary
Mind Medicine (MNMD) announces positive Phase 2b results for MM120 in Generalized Anxiety Disorder (GAD) and initiates Phase 1 trial for MM402 in Autism Spectrum Disorder (ASD). The company plans to present 12-week data for MM120 at an investor event in March, with multiple milestones expected in 2024, including Phase 3 program initiation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.78%
Tags
Rhea-AI Summary
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announces a conference call to provide a corporate update and review the results for the year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
conferences earnings
Mind Medicine Inc

Nasdaq:MNMD

MNMD Rankings

MNMD Stock Data

681.74M
33.11M
2.42%
25.4%
10.25%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Vancouver

About MNMD

Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.